-+ 0.00%
-+ 0.00%
-+ 0.00%

OLEMA ONCOLOGY ANNOUNCES ENCOURAGING INITIAL CLINICAL DATA FROM THE PHASE 1 STUDY OF OP-3136, A KAT6 INHIBITOR, AT 2026 ASCO ANNUAL MEETING

Reuters·05/21/2026 21:00:00

Please log in to view news